Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose Zemaira for Lung Inflammation in AATD
NCT01669421Phase 2Completed
- Start
- Jul 2012
- Primary completion
- May 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alpha1-proteinase inhibitor in alpha-1 antitrypsin deficiency (AATD). Primary endpoint: Changes in Inflammatory Biomarkers in Bronchoalveolar Lavage Fluid at Week 12. Started Jul 2012; status: completed.
02
Drugs
alpha1-proteinase inhibitor
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NCT01669421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01669421.